A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin.

Lee, Suk-Young; Kim, Hye Sook; Choi, Yoon Ji; Park, Kyong Hwa; Shin, Sang Won; Kim, Yeul Hong; Tae Kim, Seung

Lee, Suk-Young; Kim, Hye Sook; Choi, Yoon Ji; Park, Kyong Hwa; Shin, Sang Won; Kim, Yeul Hong; Tae Kim, Seung.

Affiliation

Lee SY; 1Division of Hematology and Oncology, Department of Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea; and 2Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Am J Ther ; 23(6): e1449-e1455, 2016.

Article in En | MEDLINE | ID: mdl-25285672

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Bile Duct Neoplasms/drug therapy; Cholangiocarcinoma/drug therapy; Liver Neoplasms/drug therapy; Adult; Aged; Bile Duct Neoplasms/pathology; Cholangiocarcinoma/pathology; Cisplatin/administration & dosage; Deoxycytidine/administration & dosage; Deoxycytidine/analogs & derivatives; Disease-Free Survival; Female; Humans; Liver Neoplasms/pathology; Male; Middle Aged; Models, Theoretical; Multivariate Analysis; Prognosis; Survival Rate; Gemcitabine

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Bile Duct Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Cholangiocarcinoma / Liver Neoplasms Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Am J Ther Journal subject: TERAPEUTICA Year: 2016 Type: Article Affiliation country: South Korea

Search on Google

XML

PubMed Links